Literature DB >> 21833467

Identification of immunity-related genes in prostate cancer and potential role of the ETS family of transcription factors in their regulation.

David Adler1, Andreas Lindstrot, Jörg Ellinger, Sebastian Rogenhofer, Reinhard Buettner, Nicolas Wernert.   

Abstract

The role of the immune response in tumor progression, and disease outcome is still debated, and a lack of knowledge of the immune defenses in prostate cancer still exists. In addition, the ETS family of transcription factors which is involved in translocations frequently found in prostate cancer is reported to be essential for the regulation of immunity-related genes. In order to identify immunity-related genes in prostate cancer, we performed two microarrays using RNA extracted from laser microdissected glands of the normal prostate proper (or the peripheral zone) and moderately and poorly differentiated prostate carcinomas from patients who had undergone radical prostatectomy. Many differentially expressed genes were found, however, only immunity-related genes (B cell, innate, and T cell immunity) with an expression of more than 10-fold increase or decrease and a P<0.01 between the moderately differentiated tumors and the normal glands, and the poorly differentiated tumors and the normal glands were considered significant. Based on these two microarrays, we identified a set of 37 genes that were up- or down-regulated in tumors (moderately and poorly differentiated) compared to the normal glands. Analysis of these genes revealed, strikingly, that 31/37 of these genes have potential binding sites within their promoter regions for members of the ETS family of transcription factors, and some are reported to be targets of ETS members. These findings identified immunity-related genes in prostate cancer, and provided insights into their potential regulation, which may lead to a better early detection, immunotherapy, and therapeutic drug treatment of this disease. Unraveling the dynamics of the ETS-immunity-related genes will provide an invaluable insight into understanding prostate cancer immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833467     DOI: 10.3892/ijmm.2011.771

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  4 in total

1.  MiR-378 suppresses prostate cancer cell growth through downregulation of MAPK1 in vitro and in vivo.

Authors:  Qi-Guang Chen; Wei Zhou; Tao Han; Shu-Qi Du; Zhen-Hua Li; Zhe Zhang; Guang-Yi Shan; Chui-Ze Kong
Journal:  Tumour Biol       Date:  2015-09-07

2.  MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer.

Authors:  Yongbao Wei; Jinrui Yang; Lu Yi; Yinhuai Wang; Zhitao Dong; Ziting Liu; Shifeng Ou-yang; Hongtao Wu; Zhaohui Zhong; Zhuo Yin; Keqin Zhou; Yunliang Gao; Bin Yan; Zhao Wang
Journal:  Sci Rep       Date:  2014-12-18       Impact factor: 4.379

3.  Regulation of prostate cancer immunity-related genes in PC3 prostate cancer cells by ETS-1.

Authors:  David Adler; Andreas Lindstrot; Reinhard Buettner; Nicolas Wernert
Journal:  Oncol Lett       Date:  2011-12-02       Impact factor: 2.967

4.  ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer.

Authors:  David Adler; Jacqueline Ochsenfahrt; Kerstin Fuchs; Glen Kristiansen; Sven Perner; Nicolas Wernert
Journal:  Int J Mol Med       Date:  2012-08-20       Impact factor: 4.101

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.